NKGen Biotech Past Earnings Performance
Past criteria checks 0/6
NKGen Biotech's earnings have been declining at an average annual rate of -196%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 100% per year.
Key information
-196.0%
Earnings growth rate
15.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -100.0% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How NKGen Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -88 | 17 | 14 |
| 31 Mar 24 | 0 | -80 | 15 | 15 |
| 31 Dec 23 | 0 | -83 | 14 | 16 |
| 30 Sep 23 | 0 | -56 | 11 | 16 |
| 30 Jun 23 | 0 | -30 | 10 | 16 |
| 31 Mar 23 | 0 | -29 | 9 | 16 |
| 31 Dec 22 | 0 | -27 | 8 | 17 |
| 31 Dec 21 | 0 | -23 | 8 | 15 |
Quality Earnings: NKGN is currently unprofitable.
Growing Profit Margin: NKGN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if NKGN's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare NKGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NKGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: NKGN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.